ATE264111T1 - Neue indikationen für mannan-binding lectin (mbl) zur behandlung von immungeschwächten patienten - Google Patents

Neue indikationen für mannan-binding lectin (mbl) zur behandlung von immungeschwächten patienten

Info

Publication number
ATE264111T1
ATE264111T1 AT00925098T AT00925098T ATE264111T1 AT E264111 T1 ATE264111 T1 AT E264111T1 AT 00925098 T AT00925098 T AT 00925098T AT 00925098 T AT00925098 T AT 00925098T AT E264111 T1 ATE264111 T1 AT E264111T1
Authority
AT
Austria
Prior art keywords
treatment
mbl
mannan
binding lectin
prophylaxis
Prior art date
Application number
AT00925098T
Other languages
English (en)
Inventor
Steffen Thiel
Jens Christian Jensenius
Original Assignee
Steffen Thiel
Jens Christian Jensenius
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Steffen Thiel, Jens Christian Jensenius filed Critical Steffen Thiel
Application granted granted Critical
Publication of ATE264111T1 publication Critical patent/ATE264111T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4726—Lectins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Chemical And Physical Treatments For Wood And The Like (AREA)
  • Filtering Materials (AREA)
  • Wrappers (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
AT00925098T 1999-05-14 2000-05-10 Neue indikationen für mannan-binding lectin (mbl) zur behandlung von immungeschwächten patienten ATE264111T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA199900668 1999-05-14
DKPA199901508 1999-10-20
PCT/DK2000/000247 WO2000069894A2 (en) 1999-05-14 2000-05-10 Novel indications of mannan-binding lectin (mbl) in the treatment of immunocompromised individuals

Publications (1)

Publication Number Publication Date
ATE264111T1 true ATE264111T1 (de) 2004-04-15

Family

ID=26064419

Family Applications (3)

Application Number Title Priority Date Filing Date
AT03029993T ATE336260T1 (de) 1999-05-14 2000-05-10 Neue indikationen für mannan-binding lectin (mbl) zur behandlung von immungeschwächten patienten
AT00925098T ATE264111T1 (de) 1999-05-14 2000-05-10 Neue indikationen für mannan-binding lectin (mbl) zur behandlung von immungeschwächten patienten
AT00925097T ATE352620T1 (de) 1999-05-14 2000-05-10 Rekombinantes menschliches mannan-bindendes lektin

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT03029993T ATE336260T1 (de) 1999-05-14 2000-05-10 Neue indikationen für mannan-binding lectin (mbl) zur behandlung von immungeschwächten patienten

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT00925097T ATE352620T1 (de) 1999-05-14 2000-05-10 Rekombinantes menschliches mannan-bindendes lektin

Country Status (15)

Country Link
US (5) US6846649B1 (de)
EP (3) EP1402897B1 (de)
JP (2) JP2002543837A (de)
CN (2) CN1359420A (de)
AT (3) ATE336260T1 (de)
AU (2) AU779404B2 (de)
CA (2) CA2372435A1 (de)
DE (3) DE60033147T2 (de)
DK (3) DK1181038T3 (de)
ES (3) ES2219336T3 (de)
NO (2) NO20015481L (de)
NZ (2) NZ515717A (de)
PT (3) PT1181038E (de)
RU (2) RU2292217C2 (de)
WO (2) WO2000070043A1 (de)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6969601B2 (en) 1997-04-03 2005-11-29 Jensenius Jens Chr MASP-2, a complement-fixing enzyme, and uses for it
WO2000070043A1 (en) * 1999-05-14 2000-11-23 Steffen Thiel Recombinant human mannan-binding lectin
WO2002005833A1 (en) * 2000-07-13 2002-01-24 Natimmune A/S MANNAN-BINDING LECTIN (MBL) TREATMENT OF INFECTIONS IN INDIVIDUALS TREATED WITH TNF-αinhibitors
EP1186299A1 (de) * 2000-09-12 2002-03-13 Universitair Medisch Centrum Utrecht Diagnose, Verbeugung und/oder Behandlung von Atherosklerose, Infectionen und Störungen des Immunsystems
WO2002041913A1 (en) * 2000-11-27 2002-05-30 Jens Christian Jensenius Collectins as adjuvants
CN101011573A (zh) * 2001-07-23 2007-08-08 纳蒂芒公司 高分子量凝集素的生产
JP4051030B2 (ja) * 2001-08-31 2008-02-20 扶桑薬品工業株式会社 ヒトマンノース結合レクチンの精製方法、ヒトマンノース結合レクチン組成物およびヒトマンノース結合レクチンの医薬用途
EP1335932B1 (de) * 2001-10-19 2005-11-30 Natimmune A/S Isolierung von lectinen
AU2003215524A1 (en) * 2002-03-15 2003-09-29 Natimmune A/S Pharmaceutical compositions comprising mannose binding lectin
US7211396B2 (en) * 2002-04-18 2007-05-01 Antibodyshop A/S Antibody pairs and kits for immunochemical determination of mannan-binding lectin
NZ535600A (en) * 2002-04-24 2008-03-28 Queensland Inst Med Res MASP-depleted MBL compositions are superior at activating the complement cascade when compared with MBL purified in complex with its associated MASPs
AU2003246119B2 (en) * 2002-06-28 2008-02-21 Fuso Pharmaceutical Industries, Ltd. Anti-HIV agent
WO2004024925A2 (en) * 2002-09-10 2004-03-25 Natimmune A/S Collectin-complement activating protein chimeras
GB0222014D0 (en) * 2002-09-23 2002-10-30 Leuven K U Res & Dev Mannan-binding lectin
JP2007525232A (ja) 2003-01-17 2007-09-06 イースロン メディカル インコーポレイテッド レクチンアフィニティー血液透析による血液のウイルス除去方法
ES2541134T3 (es) * 2003-05-12 2015-07-16 Helion Biotech Aps Anticuerpos de MASP-2
US7135338B2 (en) * 2003-06-11 2006-11-14 Dobeel Corporation Methods for overexpression of high molecular weight form of mannose binding lectin (MBL) and a specific formulation for active treatment for systemic infection with microorganism
DE20317914U1 (de) 2003-11-19 2004-12-30 Weh, Erwin Betätigungsvorrichtung für eine Schnellanschlusskupplung
US7335633B2 (en) 2004-01-12 2008-02-26 Cornell Research Foundation, Inc. Detecting recurrent vulvovaginal candidiasis or vulvar vestibulitis syndrome and method for treating same
WO2005080594A2 (en) * 2004-02-24 2005-09-01 Innogenetics N.V. Method for determining the risk of developing a neurological disease
CA2558976A1 (en) 2004-03-09 2005-09-22 The Government Of The United States Of America, As Represented By The Se Cretary, Department Of Health And Human Services Mvl, an antiviral protein from a cyanobacterium
US7919094B2 (en) * 2004-06-10 2011-04-05 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
EP1618887A1 (de) * 2004-07-12 2006-01-25 UMC Utrecht Holding B.V. Beseitigung von Polyolen aus dem Körper
US20090247454A1 (en) * 2004-09-29 2009-10-01 Mellitus, S.L. Method for detecting a predisposition to develop gestational diabetes mellitus and treatment for this disease
EP1833502B1 (de) * 2004-12-23 2011-03-02 Council of Scientific and Industrial Research Pharmazeutische zusammensetzung zur behandlung von invasiver lungenaspergillose
WO2006071102A1 (en) * 2004-12-30 2006-07-06 Dobeel Co., Ltd. Spray-dried composition containing collectin family proteins or variants therof and process for preparing the same
CN101193651A (zh) * 2005-04-11 2008-06-04 内蒂穆恩公司 甘露聚糖结合凝集素(mbl)在治疗与癌症相关的免疫削弱的病症中的用途
US9220831B2 (en) 2005-10-06 2015-12-29 Children's Medical Center Corporation Device and method for combined microfluidic-micromagnetic separation of material in continuous flow
SI2380587T1 (en) 2005-12-21 2018-03-30 Pharming Intellectual Property B.V. Use of a C1 inhibitor to prevent ischemic reperfusion injury
WO2007085057A1 (en) * 2006-01-25 2007-08-02 The Council Of The Queensland Institute Of Medical Research A medical protocol
US20070226567A1 (en) * 2006-03-23 2007-09-27 Gorman Kevin W High speed bist utilizing clock multiplication
CN101939531A (zh) * 2008-01-16 2011-01-05 苏佩尔帕尔汽车工业和贸易有限公司 用于重型发动机平台的电动燃料泵
WO2009126346A2 (en) * 2008-01-18 2009-10-15 The General Hospital Corporation Methods for prevention and treatment of infections with supraphysiological doses of mannan-binding lectin (mbl) and ficolin-mbl fusion proteins
US9156037B2 (en) 2009-01-15 2015-10-13 Children's Medical Center Corporation Microfluidic device and uses thereof
JP5959440B2 (ja) 2010-01-19 2016-08-02 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 病原体の検出および治療のための改変オプソニン
WO2011100528A2 (en) * 2010-02-12 2011-08-18 Emory University Compositions and uses of lectins
DE102011003478A1 (de) * 2011-02-01 2012-08-02 Cytavis Biopharma Gmbh Antivirales Mittel enthaltend rekombinante Mistellektine
AU2012284097B2 (en) 2011-07-18 2017-08-03 President And Fellows Of Harvard College Engineered microbe-targeting molecules and uses thereof
WO2013130875A1 (en) 2012-02-29 2013-09-06 President And Fellows Of Harvard College Rapid antibiotic susceptibility testing
EP2875078B1 (de) 2012-07-18 2017-12-20 President and Fellows of Harvard College Modifizierung von oberflächen zur gleichzeitigen abweisung und gezielten bindung gewünschter gruppen
WO2014144325A1 (en) 2013-03-15 2014-09-18 President And Fellows Of Harvard College Methods and compositions for improving detection and/or capture of a target entity
WO2014190040A1 (en) 2013-05-21 2014-11-27 President And Fellows Of Harvard College Engineered heme-binding compositions and uses thereof
EP3083658B1 (de) 2013-12-18 2019-05-08 President and Fellows of Harvard College Detektion gram-positiver bakterien mit crp
WO2016077067A2 (en) * 2014-10-27 2016-05-19 President And Fellows Of Harvard College Magnetic capture of a target from a fluid
EP3763378A1 (de) 2015-08-06 2021-01-13 President and Fellows of Harvard College Verbesserte mikrobenbindende moleküle und verwendungen davon
JP7163192B2 (ja) 2016-05-16 2022-10-31 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ Ｃｏ２プラズマ活性化表面にカップリングする水性生体分子
CN107050436B (zh) * 2017-02-27 2020-03-17 新乡医学院 Mbl在制备预防或治疗效应t细胞引发疾病药物中的应用
CN107050427A (zh) * 2017-02-27 2017-08-18 新乡医学院 MBL在制备预防或治疗以Tregs为靶点的疾病药物中的应用
WO2019110706A1 (en) * 2017-12-08 2019-06-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the risk of developing a sepsis or a systemic inflammatory response syndrome (sirs)
RU2739113C1 (ru) * 2019-10-04 2020-12-21 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр терапии и профилактической медицины" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ ТПМ" Минздрава России) Способ определения активности маннан-связывающих лектин-ассоциированных сериновых протеаз в тесте коагуляции фибриногена
CA3238612A1 (en) * 2021-11-18 2023-05-25 Francis V. A. FERNANDES Recombinant proteins

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE165980T1 (de) 1987-08-20 1998-05-15 Childrens Medical Center Nukleinsaürefragmente, die mannose bindende fragmente vom menschlichen mannosebindenden protein kodieren
US5270199A (en) 1987-08-20 1993-12-14 The Children's Medical Center Corporation Human mannose-binding protein
US5112952A (en) 1990-09-28 1992-05-12 Pierce Chemical Company Composition and method for isolation and purification of Immunoglobulin M
CA2229775C (en) 1995-08-17 2003-07-22 Fuso Pharmaceutical Industries, Ltd. Recombinant conglutinin and producing method thereof
DE69836428T2 (de) 1997-08-21 2007-09-27 Takara Bio Inc., Otsu Karzinostatische wirkstoffe
NZ509089A (en) * 1998-06-10 2002-10-25 Statens Seruminstitut Affinity chromatography purification for production of mannan-binding lectin
WO2000070043A1 (en) * 1999-05-14 2000-11-23 Steffen Thiel Recombinant human mannan-binding lectin

Also Published As

Publication number Publication date
US6562784B1 (en) 2003-05-13
DE60030173D1 (de) 2006-09-28
ES2219336T3 (es) 2004-12-01
AU781135B2 (en) 2005-05-05
EP1181038A2 (de) 2002-02-27
DK1181363T3 (da) 2007-05-29
EP1402897B1 (de) 2006-08-16
WO2000069894A3 (en) 2001-02-08
EP1181363B1 (de) 2007-01-24
AU4393600A (en) 2000-12-05
ATE352620T1 (de) 2007-02-15
US20030191052A1 (en) 2003-10-09
PT1181363E (pt) 2007-05-31
NO20015506D0 (no) 2001-11-09
PT1402897E (pt) 2007-01-31
RU2005125625A (ru) 2007-02-20
ES2271468T3 (es) 2007-04-16
NO20015481L (no) 2002-01-11
WO2000069894A2 (en) 2000-11-23
US7202207B2 (en) 2007-04-10
AU4393500A (en) 2000-12-05
DE60030173T2 (de) 2007-08-23
AU779404B2 (en) 2005-01-20
DE60009896T2 (de) 2005-04-21
ATE336260T1 (de) 2006-09-15
US20070197428A1 (en) 2007-08-23
DE60033147T2 (de) 2007-12-13
EP1181038B1 (de) 2004-04-14
CN1359298A (zh) 2002-07-17
EP1402897A3 (de) 2004-06-30
US6846649B1 (en) 2005-01-25
US20040229212A1 (en) 2004-11-18
JP2002543837A (ja) 2002-12-24
WO2000070043A1 (en) 2000-11-23
CA2372128A1 (en) 2000-11-23
NZ515718A (en) 2004-03-26
NO20015506L (no) 2002-01-09
DK1181038T3 (da) 2004-08-09
NZ515717A (en) 2004-01-30
ES2281341T3 (es) 2007-10-01
PT1181038E (pt) 2004-08-31
DE60009896D1 (de) 2004-05-19
EP1181363A1 (de) 2002-02-27
CA2372435A1 (en) 2000-11-23
EP1402897A2 (de) 2004-03-31
DE60033147D1 (de) 2007-03-15
DK1402897T3 (da) 2006-12-27
NO20015481D0 (no) 2001-11-08
RU2292217C2 (ru) 2007-01-27
US7439224B2 (en) 2008-10-21
CN1359420A (zh) 2002-07-17
JP2002544286A (ja) 2002-12-24

Similar Documents

Publication Publication Date Title
ATE264111T1 (de) Neue indikationen für mannan-binding lectin (mbl) zur behandlung von immungeschwächten patienten
DE60119534D1 (de) Verwendung von hydroxyethylrutosiden zur behandlung von erkältungssymptomen, symptomen der allergischen rhinitis und atemwegsinfektionen
DE60231804D1 (de) Verwendung von hepcidin zur herstellung eines arzneimittels zur behandlung von eisenhomöostase störungen
EP2769715A3 (de) Verfahren zur Behandlung von Autoimmunkrankheiten und damit zusammenhängende Reagenzien
MA25775A1 (fr) Combinaison des bacteries d'acide lactique et son utilisation pour la prevention et/ou le traitement des infections et des etats inflammatoires.
FI961438A0 (fi) beta-amyloidiproteiinituotannon estäjiä
ATE91628T1 (de) Sauerwiderstehender fibroblast-wachstumsfaktor, zubereitung zur behandlung von magen-darmweggeschw¨rkrankheiten.
DE602004016729D1 (de) 1-phenylalkancarbonsäurederivate zur behandlung neurodegenerativer erkrankungen
DE69233108D1 (de) Hemmstoffe für menschliche neutrophile elastase und menschliches kathepsin g
NZ263344A (en) Human bactericidal/permeability increasing (bpi) protein functional domain peptides and their use
ATE475716T1 (de) Zusammenstellungen zur behandlung von neurodegenerativen erkrankungen
HUP0103889A2 (hu) Kopolimer-1-rokon polipeptidek alkalmazása molekulatömeg kalibráló standardként és gyógyászati anyagként
MA27929A1 (fr) Utilisation de calcitonine pour le traitement de l'osteoarthrite
BG105302A (en) Means for improving cognition
DE60025026D1 (de) Antimicrobielle wirkung des ersten kationischen cluster des menschlichen lactoferrins
ATE204759T1 (de) Verwendung von hyperforin und hyperforinhaltigen extrakten zur behandlung und prophylaxe von demenzerkrankungen
DE60118769D1 (de) Verwendung von langem pentraxin ptx3 zur behanlung von durch geänderte aktivität des fgf-2 wachstumsfaktors hervorgerufene krankheiten
NZ228068A (en) Brominated or chlorinated allylamines and their pharmaceutical compositions
HUP9903688A2 (hu) Olanzapin alkalmazása az autizmus kezelésére szolgáló gyógyszerkészítmény előállítására
DE60011601D1 (de) Rekombinantes sp-a zur behandlung und vorbeugung von pulmonaren infektionen und entzündungen
DE69424679D1 (de) Zusammensetzung zur behandlung oder vorbeugung von herpes
AU9184901A (en) Use of il-6r/il-6 chimera in huntington's disease
DE60229624D1 (de) Peroxiredoxin-arzneistoffe zur behandlung einer hiv-1-infektion
ATE312611T1 (de) Verwendung von mizolastine zur herstellung eines arzneimittels zur behandlung von entzündungen
PT1355650E (pt) Combinacao de ingredientes activos contendo alfuzosina e apomorfina

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1181038

Country of ref document: EP

REN Ceased due to non-payment of the annual fee